2.4+Agents+for+Type+2+Diabetes+I

Hypoglycemia is ___ with GLP-1.

Hypoglycemia is ___ with Dipeptidyl Peptidase 4 Inhibitors.

Meglitinides are similar to ___ in their function.

Sulfonylureas increase ___ secretion from pancreatic beta cells.

Meglitinides increase ___ secretion from pancreatic beta cells.

Type I Diabetes is primarily caused by the ___ of insulin-producing beta cells.

The direct effect of sulfonylureas is to ___ insulin release.

Incretin-based therapies mimic the effects of ___ produced GLP-1.

An example of a meglitinide is ___ (Prandin).

In Type II Diabetes, the body becomes resistant to ___ or doesn't produce enough of it.

Sulfonylureas have an indirect and direct effect of decreasing hepatic ___ production.

GLP-1 helps improve the size and function of ___ cells.

Another example of a meglitinide is ___ (Starlix).

Type I Diabetes is often diagnosed in ___, while Type II Diabetes is more common in ___ adults.

Incretin-based therapies involve hormones such as ___ and ___.

Sulfonylureas increase glucose entry into ___ and other peripheral tissues.

Incretins decrease glucagon release from pancreatic ___ cells.

Meglitinides are considered to be relatively ___ acting.

Individuals with Type I Diabetes require ___ for management.

Adverse effects of sulfonylureas include ___, which can occur due to higher doses, missing meals, or strenuous exercise.

The overall effect of sulfonylureas is to lower ___ sugar.

Sulfonylureas are typically used in the ___ stages of the disease.

One effect of GLP-1 is to reduce ___ and help promote weight loss.

Type II Diabetes can often be managed with ___ and lifestyle changes.

Meglitinides can be used in combination with other ___.

Symptoms of hypoglycemia from sulfonylureas may include ___, fatigue, and tachycardia.

Sulfonylureas require reasonable ___ cell function.

GLP-1 and GIP are hormones released from the ___ tract after eating.

Exenatide is also known as ___ and is administered sub-Q.

Severe hypoglycemia can lead to ___, convulsions, and death.

Incretins regulate the secretion and effects of ___.

One common sulfonylurea is ___ (Dymelor).

Liraglutide is marketed under the name ___ and is a type of GLP-1.

Adverse effects of meglitinides include ___, which can occur due to higher doses, missing meals, or strenuous exercise.

Gastrointestinal adverse effects of sulfonylureas include ___, nausea, and diarrhea.

In Type 2 DM, GLP-1 levels may be ___, while GIP levels are typically ___.

___ (Diabinese) is another common sulfonylurea.

Symptoms of hypoglycemia from meglitinides may include ___, fatigue, and tachycardia.

Other adverse effects of sulfonylureas may include headache, dizziness, skin rashes, and ___ abnormalities.

Two options for incretin-based therapies are GLP-1 receptor agonists and ___ inhibitors.

Incretin-based therapies primarily involve the use of ___ inhibitors.

___ (Amaryl) is a commonly used sulfonylurea.

Severe hypoglycemia can result in ___, convulsions, and death.

DPP4 inhibitors work by inhibiting ___, an enzyme that breaks down incretins.

___ (Glucotrol) is a type of sulfonylurea.

Gastrointestinal adverse effects of meglitinides include ___, nausea, and diarrhea.

Incretin-based therapies help to prolong the effects of ___ and ___.

___ (DiaBeta, Micronase) is a common sulfonylurea medication.

Other adverse effects may include headache, bronchitis, and ___ pain.

One of the benefits of incretin-based therapies is that they can reduce ___ and promote weight loss.

___ (Tolinase) is classified as a sulfonylurea.

___ are agents that stimulate insulin secretion in patients with Type 2 Diabetes.

Examples of DPP4 inhibitors include Linagliptin (Tradjenta), Sitagliptin (___), and Saxagliptin (Onglyza).

___ (Orinase) is a common agent in the sulfonylureas category.

___ are a class of medications that also stimulate insulin secretion but have a shorter duration of action compared to sulfonylureas.

DPP4 inhibitors are administered in ___ form.

___ are therapies that enhance the effects of incretin hormones to improve insulin secretion.

___ are medications that improve insulin sensitivity in the body.

___ is a class of drugs that decreases hepatic glucose production and increases insulin sensitivity.

___ are a type of insulin sensitizer that works by activating PPAR-gamma.

___ inhibit the enzyme that breaks down carbohydrates in the intestine.

___ is an injectable medication that helps control blood sugar levels by slowing gastric emptying.

___ are used to lower blood sugar levels by binding bile acids in the intestine.